Simultaneous dose and dose rate optimization via dose modifying factor modeling for FLASH effective dose.
Ma J, Lin Y, Tang M, Zhu YN, Gan GN, Rotondo RL, Chen RC, Gao H.
Med Phys. 2024 Aug;51(8):5190-5203. doi: 10.1002/mp.17251. Epub 2024 Jun 14.
Dose-modifying factor for captopril for mitigation of radiation injury to normal lung.
Medhora M, Gao F, Fish BL, Jacobs ER, Moulder JE, Szabo A.
J Radiat Res. 2012 Jul;53(4):633-40. doi: 10.1093/jrr/rrs004. Epub 2012 Jun 6.
Electron vs proton FLASH radiation on murine skin toxicity.
Kristensen L, Rohrer S, Hoffmann L, Præstegaard LH, Ankjærgaard C, Andersen CE, Kanouta E, Johansen JG, Sahlertz M, Nijkamp J, Poulsen PR, Sørensen BS.
Radiother Oncol. 2025 May;206:110796. doi: 10.1016/j.radonc.2025.110796. Epub 2025 Feb 19.
Toward a Transportable Cell Culture Platform for Evaluating Radiotherapy Dose Modifying Factors.
Carlson N, House CD, Tambasco M.
Int J Mol Sci. 2023 Nov 3;24(21):15953. doi: 10.3390/ijms242115953.
Simultaneous dose and dose rate optimization (SDDRO) of the FLASH effect for pencil-beam-scanning proton therapy.
Gao H, Liu J, Lin Y, Gan GN, Pratx G, Wang F, Langen K, Bradley JD, Rotondo RL, Li HH, Chen RC.
Med Phys. 2022 Mar;49(3):2014-2025. doi: 10.1002/mp.15356. Epub 2021 Dec 7.
Sample-size calculation for preclinical dose-response experiments using heterogeneous tumour models.
Ciecior W, Ebert N, Borgeaud N, Thames HD, Baumann M, Krause M, Löck S.
Radiother Oncol. 2021 May;158:262-267. doi: 10.1016/j.radonc.2021.02.032. Epub 2021 Mar 3.
Protection of sildenafil citrate hydrogel against radiation-induced skin wounds.
Kulshrestha S, Chawla R, Singh S, Yadav P, Sharma N, Goel R, Ojha H, Kumar V, Adhikari JS.
Burns. 2020 Aug;46(5):1157-1169. doi: 10.1016/j.burns.2019.11.020. Epub 2019 Dec 20.
Epithelial-mesenchymal crosstalk induces radioresistance in HNSCC cells.
Steinbichler TB, Alshaimaa A, Maria MV, Daniel D, Herbert R, Jozsef D, Ira-Ida S.
Oncotarget. 2017 Dec 14;9(3):3641-3652. doi: 10.18632/oncotarget.23248. eCollection 2018 Jan 9.
Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis.
Wu X, Wang L, Shen L, Tang K.
EBioMedicine. 2022 Jul;81:104102. doi: 10.1016/j.ebiom.2022.104102. Epub 2022 Jun 24.
Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
Brand DH, Brüningk SC, Wilkins A, Fernandez K, Naismith O, Gao A, Syndikus I, Dearnaley DP, Tree AC, van As N, Hall E, Gulliford S; CHHiP Trial Management Group.
Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):596-608. doi: 10.1016/j.ijrobp.2020.12.041. Epub 2021 Jan 4.
